A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING-DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACODYNAMICS, AND PHARMACOKINETICS OF XMAB®27564 IN PATIENTS WITH PLAQUE PSORIASIS
- Registry ID
- XMAB27564-02
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- XENCOR INC.
- Start date
- 2024-08-09
- Last update
- 2022-05-13
Conditions
Related clinical trials
- AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF ORKA-001 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED DOSE-RANGE FINDING STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORKA-002 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
- MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, PLACEBO CONTROLLED, DOSE-RANGE FINDING STUDY OF ORKA-001 IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
- A PHASE 3B/4 MULTI-CENTER, RANDOMIZED, OPEN-LABEL, LONG-TERM
SAFETY STUDY OF DEUCRAVACITINIB IN COMPARISON TO USTEKINUMAB IN
PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS
(PRAGMATYK)
- A MULTICENTER, RANDOMIZED, DOUBLE-BLINDED,
PLACEBO -CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND
PHARMACOKINETICS OF ORKA-001 IN PARTICIPANTS WITH MODERATE-TO-SEVERE
PLAQUE PSORIASIS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OFDEUCRAVACITINIB IN ADOLESCENT PARTICIPANTS (12 YEARS TO LESS THAN 18YEARS) WITH MODERATE TO SEVERE PLAQUE PSORIASIS
View on source registry